国际接触性皮炎研究组内进行的100ppm和200ppm甲基氯异噻唑啉酮/甲基异噻唑啉酮的多中心斑贴试验。
Multicenter Patch Testing With Methylchloroisothizoline/Methylisothiazolinone in 100 and 200 ppm Within the International Contact Dermatitis Research Group.
作者信息
Engfeldt Malin, Ale Iris, Andersen Klaus E, Elsner Peter, Goh Chee-Leok, Goossens An, Jerajani Hemangi, Matsunaga Kayoko, Bruze Magnus
机构信息
From the *Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden; †Allergy Center and Department of Dermatology, University Hospital, Republic University of Uruguay, Montevideo; ‡Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark; §Department of Dermatology, University Hospital Jena, Germany; ∥Department of Dermatology, National Skin Center, Singapore, Singapore; ¶Contact Allergy Unit, Department of Dermatology, University Hospital K.U. Leuven, Belgium; #MGM Medical College, Mumbai, India; and **Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
出版信息
Dermatitis. 2017 May/Jun;28(3):215-218. doi: 10.1097/DER.0000000000000287.
BACKGROUND
The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series.
OBJECTIVES
The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world.
PATIENTS AND METHODS
Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series.
RESULTS
Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P < 0.001).
CONCLUSIONS
Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 μg/cm) diagnoses significantly more contact allergy than 0.01% (dose, 3 μg/cm), without resulting in more adverse reactions. Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series.
背景
防腐剂甲基氯异噻唑啉酮/甲基异噻唑啉酮（MCI/MI）是一种众所周知的接触性致敏剂。从历史上看，对于MCI/MI的最佳斑贴试验浓度存在不同意见，有人提出使用0.01%和0.02%的水溶液。2011年，基于文献综述，建议在国际基线系列中使用0.02%的水溶液浓度。
目的
本研究的目的是通过比较来自世界各地代表不同国家的诊所中连续使用0.01%和0.02% MCI/MI进行斑贴试验的结果，来验证2011年的建议。
患者和方法
来自8个国家的8家皮肤科诊所的2703例连续性皮炎患者接受了0.01% MCI/MI水溶液的斑贴试验，并同时接受0.02% MCI/MI水溶液的斑贴试验，这些患者被临时纳入基线系列。
结果
分别在3.7%和5.6%的患者中发现对0.01%和0.02%的MCI/MI有接触性过敏（P < 0.001）。
结论
0.02%水溶液（剂量为6 μg/cm）的甲基氯异噻唑啉酮/MI诊断出的接触性过敏明显多于0.01%（剂量为3 μg/cm），且不会导致更多不良反应。因此，0.02%水溶液的甲基氯异噻唑啉酮/MI应继续用于国际基线系列。
Zotero 插件